{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:03:35Z","timestamp":1785229415719,"version":"3.55.0"},"reference-count":54,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Endocrino Diabet &amp; Metabol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction\u2010associated steatotic liver disease (MASLD) is increasingly prevalent and associated with obesity and dyslipidemia, yet effective pharmacological interventions remain limited. Empagliflozin has shown potential benefits in MASLD, although evidence remains limited. This systematic review and meta\u2010analysis assesses the efficacy of empagliflozin in patients with MASLD, both diabetic and non\u2010diabetic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An advanced database search was conducted up to June 1st, 2026, to identify eligible randomized controlled trials (RCTs). The relevant data were extracted from selected studies. Pooled effect sizes were calculated as weighted mean differences (WMDs) with 95% confidence intervals (CIs) using a random\u2010effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven RCTs comprising 591 participants were included. Empagliflozin significantly improved liver enzyme profiles. Specifically, it reduced alanine aminotransferase (ALT) (WMD: \u221212.24\u2009IU\/L;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.037), aspartate aminotransferase (AST) (WMD: \u22129.51\u2009IU\/L;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.048), and gamma\u2010glutamyl transferase (GGT) (WMD: \u221214.92\u2009IU\/L;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023). Reductions in alkaline phosphatase (ALP) were observed but did not reach statistical significance (WMD: \u221226.28\u2009IU\/L;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.292). Although substantial heterogeneity was observed for several liver enzyme outcomes. Empagliflozin had no significant effect on lipid parameters, including triglycerides (TG), total cholesterol (TC), low\u2010density and high\u2010density lipoprotein cholesterols (LDL\u2010C, HDL\u2010C). Empagliflozin also produced a statistically significant but modest reduction in body mass index (BMI) (WMD: \u22120.71\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Empagliflozin also produced a statistically significant but clinically modest reduction in BMI (WMD: \u22120.71\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; 95% CI: \u22121.00 to \u22120.43;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Empagliflozin appears to improve liver enzymes and modestly reduce BMI in patients with MASLD, while having a neutral effect on lipid parameters. These findings may confer a statistically significant but clinically modest benefit, particularly in patients with coexisting metabolic risk factors. However, the evidence is limited by small sample sizes, short follow\u2010up periods, and potential publication bias; therefore, the conclusions should be considered preliminary and hypothesis\u2010generating.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/edm2.70294","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:41:36Z","timestamp":1785130896000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and\n                    <scp>BMI<\/scp>\n                    in Patients With Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (\n                    <scp>MASLD<\/scp>\n                    ): A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4388-0214","authenticated-orcid":false,"given":"Mehdi","family":"Karimi","sequence":"first","affiliation":[{"name":"Faculty of Medicine Bogomolets National Medical University (NMU)  Kyiv Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1883-5095","authenticated-orcid":false,"given":"Ali","family":"Tahmasebi","sequence":"additional","affiliation":[{"name":"Student Research Committee Tabriz University of Medical Sciences  Tabriz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4735-0859","authenticated-orcid":false,"given":"Sepehr","family":"Ramezanipour","sequence":"additional","affiliation":[{"name":"Student Research Committee Fasa University of Medical Sciences  Fasa Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3828-3841","authenticated-orcid":false,"given":"Fatemeh Naseri","family":"Rad","sequence":"additional","affiliation":[{"name":"Student Research Committee, School of Medicine Iran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1609-9493","authenticated-orcid":false,"given":"Fereshteh","family":"Valizadeh","sequence":"additional","affiliation":[{"name":"School of Medicine Shahid Beheshti University of Medical Sciences (SBUMS)  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2743-1998","authenticated-orcid":false,"given":"Pegah","family":"Abedi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Isfahan University of Medical Sciences  Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3287-5539","authenticated-orcid":false,"given":"Meisam","family":"Gholami","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Islamic Azad University, Tehran Medical Science Branch  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1807-8939","authenticated-orcid":false,"given":"Narges","family":"Sobhan Ardekani","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Isfahan University of Medical Sciences  Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-6098","authenticated-orcid":false,"given":"Manijeh Ebrahimzadeh","family":"Pirshahid","sequence":"additional","affiliation":[{"name":"Student Research Committee, Health Research Institute Babol University of Medical Sciences  Babol Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,26]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2024.2374472"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28468"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17846"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156004"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00599-1"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00318-8"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2026.100822"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2024.2335829"},{"issue":"1","key":"e_1_2_14_10_1","first-page":"1","article-title":"Efficacy of N\u2010Acetylcysteine on Liver Function and Metabolic Profiles in Patients With Metabolic Dysfunction\u2010Associated Steatotic Liver Disease (MASLD): A Double\u2010Blind, Randomized Controlled Trial","volume":"17","author":"Sinaeinejad M.","year":"2025","journal-title":"Addiction and Health"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/fsn3.70588"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/lipd.70042"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S69926"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0937-z"},{"issue":"7","key":"e_1_2_14_15_1","article-title":"The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non\u2010Alcoholic Fatty Liver Disease","volume":"13","author":"Pokharel A.","year":"2021","journal-title":"Cureus"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1393946"},{"issue":"1","key":"e_1_2_14_17_1","article-title":"The Effect of Empagliflozin on Non\u2010Alcoholic Steatohepatitis and Liver Enzymes Levels in Patients With Type 2 Diabetes Mellitus: A Randomized Clinical Trial","volume":"25","author":"Mehr K. N.","year":"2025","journal-title":"Hepatitis Monthly"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000855"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-025-01882-8"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.836455"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v22i3.42"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2020-209567"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtumed.2025.07.008"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119099369.ch22"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01498-5"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01011-3"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-02084-x"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1712586"},{"issue":"8","key":"e_1_2_14_33_1","article-title":"Empagliflozin Treatment for Non\u2010Alcoholic Fatty Liver Disease in Type 2 Diabetes Patients: A Systematic Review and Meta\u2010Analysis of Randomized Controlled Trials","volume":"17","author":"Alsarkhi L. N.","year":"2025","journal-title":"Cureus"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g4596"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4702-3"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.793586"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2019.01.016"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105782"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164115616901"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12188"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2286"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-83820-7"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-024-02389-2"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-021-00501-9"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2294046"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31518"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0355-3"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S50773"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000783"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.09.001"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164114561992"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ14-0335"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3828"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0058"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70294","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/edm2.70294","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:30:43Z","timestamp":1785227443000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/edm2.70294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/edm2.70294"],"URL":"https:\/\/doi.org\/10.1002\/edm2.70294","archive":["Portico"],"relation":{},"ISSN":["2398-9238","2398-9238"],"issn-type":[{"value":"2398-9238","type":"print"},{"value":"2398-9238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70294"}}